[
  {
    "ts": "2025-12-10T09:30:00+00:00",
    "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
    "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
    "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
    "source": "South China Morning Post",
    "provider": "yfinance",
    "raw": {
      "id": "e5809500-2c36-38a7-8c06-27c432a47945",
      "content": {
        "id": "e5809500-2c36-38a7-8c06-27c432a47945",
        "contentType": "STORY",
        "title": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
        "description": "",
        "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
        "pubDate": "2025-12-10T09:30:00Z",
        "displayTime": "2025-12-10T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c",
          "originalWidth": 1999,
          "originalHeight": 1445,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NrMYkjybZfgvsVPgy08KfA--~B/aD0xNDQ1O3c9MTk5OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 1999,
              "height": 1445,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vF.Bc5MyIqpbyFQCk.k5zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "South China Morning Post",
          "url": "https://www.scmp.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T11:26:24+00:00",
    "headline": "Eli Lilly to Invest $6 Billion in New Alabama Manufacturing Plant",
    "summary": "Project expands U.S. production capacity as demand for weight-loss drugs grows",
    "url": "https://finance.yahoo.com/news/eli-lilly-invest-6-billion-112624910.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "176ccaa8-d330-3901-87e7-f36c25fcec63",
      "content": {
        "id": "176ccaa8-d330-3901-87e7-f36c25fcec63",
        "contentType": "STORY",
        "title": "Eli Lilly to Invest $6 Billion in New Alabama Manufacturing Plant",
        "description": "",
        "summary": "Project expands U.S. production capacity as demand for weight-loss drugs grows",
        "pubDate": "2025-12-10T11:26:24Z",
        "displayTime": "2025-12-10T11:26:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/a1909c71d31e292152d3197b5f27917c",
          "originalWidth": 6000,
          "originalHeight": 3706,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MLqkjh0Drws9ZgXQtGDNWg--~B/aD0zNzA2O3c9NjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/a1909c71d31e292152d3197b5f27917c.cf.webp",
              "width": 6000,
              "height": 3706,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x9UH0owPssXacsAptT_sDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a1909c71d31e292152d3197b5f27917c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-invest-6-billion-112624910.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-invest-6-billion-112624910.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T11:20:41+00:00",
    "headline": "Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility",
    "summary": "The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-6bn-alabama-orforglipron-manufacturing-site/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "6a7a7160-0046-3e1f-b713-e9a632f5d9f7",
      "content": {
        "id": "6a7a7160-0046-3e1f-b713-e9a632f5d9f7",
        "contentType": "STORY",
        "title": "Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility",
        "description": "",
        "summary": "The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.",
        "pubDate": "2025-12-10T11:20:41Z",
        "displayTime": "2025-12-10T11:20:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/ab955fa9fcfb1a1d2efe45f7f9101165",
          "originalWidth": 1000,
          "originalHeight": 421,
          "caption": "Eli Lilly is expanding its US drug manufacturing footprint with a new $6bn orforglipron production site in Huntsville",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6Yd7ZcoDaGRq3C05sCy4lw--~B/aD00MjE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/ab955fa9fcfb1a1d2efe45f7f9101165.cf.webp",
              "width": 1000,
              "height": 421,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qd3rQq0Cel1iReM47OHyqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/ab955fa9fcfb1a1d2efe45f7f9101165.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-6bn-alabama-orforglipron-manufacturing-site/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-picks-alabama-home-112041123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T12:43:00+00:00",
    "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
    "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
    "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "21ccecca-5adc-31eb-bc07-c7accb75b166",
      "content": {
        "id": "21ccecca-5adc-31eb-bc07-c7accb75b166",
        "contentType": "STORY",
        "title": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
        "description": "",
        "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
        "pubDate": "2025-12-10T12:43:00Z",
        "displayTime": "2025-12-10T12:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T16:28:38+00:00",
    "headline": "Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-162838877.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1f3af0b1-40ed-360e-aa30-b6480ff0c968",
      "content": {
        "id": "1f3af0b1-40ed-360e-aa30-b6480ff0c968",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]",
        "pubDate": "2025-12-10T16:28:38Z",
        "displayTime": "2025-12-10T16:28:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-162838877.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-162838877.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T15:53:47+00:00",
    "headline": "Eli Lilly Plans $6B Investment in New Alabama Manufacturing Site",
    "summary": "Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.",
    "url": "https://finance.yahoo.com/news/eli-lilly-plans-6b-investment-155347335.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "c0a6b7b0-57ca-3555-a3f4-7fb9a2e0dc63",
      "content": {
        "id": "c0a6b7b0-57ca-3555-a3f4-7fb9a2e0dc63",
        "contentType": "STORY",
        "title": "Eli Lilly Plans $6B Investment in New Alabama Manufacturing Site",
        "description": "",
        "summary": "Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.",
        "pubDate": "2025-12-10T15:53:47Z",
        "displayTime": "2025-12-10T15:53:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-plans-6b-investment-155347335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-plans-6b-investment-155347335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T15:17:00+00:00",
    "headline": "Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?",
    "summary": "Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.",
    "url": "https://finance.yahoo.com/news/nvo-defend-obesity-lead-glp-151700548.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6f58e118-e9e6-36eb-ade7-31b833496b00",
      "content": {
        "id": "6f58e118-e9e6-36eb-ade7-31b833496b00",
        "contentType": "STORY",
        "title": "Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?",
        "description": "",
        "summary": "Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.",
        "pubDate": "2025-12-10T15:17:00Z",
        "displayTime": "2025-12-10T15:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvo-defend-obesity-lead-glp-151700548.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvo-defend-obesity-lead-glp-151700548.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T21:35:00+00:00",
    "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "summary": "Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.",
    "url": "https://www.fool.com/investing/2025/12/10/warning-this-skyrocketing-stock-has-a-hidden-risk/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9490c0dc-10be-3486-8b72-7095429b3fe6",
      "content": {
        "id": "9490c0dc-10be-3486-8b72-7095429b3fe6",
        "contentType": "STORY",
        "title": "Warning: This Skyrocketing Stock Has a Hidden Risk",
        "description": "",
        "summary": "Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.",
        "pubDate": "2025-12-10T21:35:00Z",
        "displayTime": "2025-12-10T21:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a07555a7d625ae48dd2ad06e882a6a94",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A person using an injection pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5OD6XUOaVqaivQYiZF3HkA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/a07555a7d625ae48dd2ad06e882a6a94.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C6jzmUgFT3EafhOGfkcTYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a07555a7d625ae48dd2ad06e882a6a94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/10/warning-this-skyrocketing-stock-has-a-hidden-risk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/warning-skyrocketing-stock-hidden-risk-213500684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T21:15:54+00:00",
    "headline": "Hims stock falls after lawmakers propose GLP-1 compounding restrictions",
    "summary": "Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.",
    "url": "https://finance.yahoo.com/news/hims-stock-falls-lawmakers-propose-211554501.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "4eb02d4f-dc07-3e78-bc48-edb0ef9bc9ea",
      "content": {
        "id": "4eb02d4f-dc07-3e78-bc48-edb0ef9bc9ea",
        "contentType": "STORY",
        "title": "Hims stock falls after lawmakers propose GLP-1 compounding restrictions",
        "description": "",
        "summary": "Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.",
        "pubDate": "2025-12-10T21:15:54Z",
        "displayTime": "2025-12-10T21:15:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hims-stock-falls-lawmakers-propose-211554501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hims-stock-falls-lawmakers-propose-211554501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]